ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Abaloparatide-Zoledronate combination protects against 4-vinylcyclohexene diepoxide-induced postmenopausal osteoporosis in mice: an osteoanabolic-antiresorptive approach.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abaloparatide, a 34-amino acid synthetic peptide analog of parathyroid hormone-related protein (PTHrP), was approved for treating postmenopausal osteoporosis in high-risk individuals or those resistant to existing drugs. This study aimed to investigate the impact of abaloparatide (20 µg/kg/d; s.c.), an osteoanabolic drug with an antiresorptive drug zoledronate (125 µg/kg i.v.) twice weekly for a month against 4-vinylcyclohexene diepoxide (VCD)-induced postmenopausal osteoporosis in mice. Female Swiss albino mice were made ovotoxic by treatment with VCD (160 mg/kg/d) for 15 days to mimic a postmenopausal state, confirmed by primordial follicle destruction in histopathological assessment. Microarchitectural analysis of distal femoral epiphysis and cortical mid-diaphysis was carried out using micro-computed tomography. Histopathological evaluation of bone, along with bone markers such as N-terminal propeptide of type 1 procollagen (P1NP) levels, C-terminal cross-linking telopeptide of type 1 collagen (CTX-1), soluble receptor activator of nuclear factor-kappa B ligand (RANKL), and osteoprotegerin (OPG) were assessed. The VCD-treated mice exhibited bone loss as evidenced through micro CT and histopathology. Treatment with abaloparatide and zoledronate combination for 30 days reversed VCD-induced alterations of BV/TV, BMD, Tb.N, and Tb.Sp, while the individual treatments were only partially effective. Serum analysis indicated reduced bone turnover in VCD-treated mice. The abaloparatide individually and in combination reversed the VCD-induced alterations in P1NP, CTX-1, and RANKL. The combination therapy also lowered the RANKL/OPG ratio. These findings suggest that the combined approach of osteoanabolic and antiresorptive treatment may offer superior protection compared to individual therapies, holding promise for postmenopausal osteoporosis treatment.
Indexed as
Identifiers
41579168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.